Research
Hormonal
Pioglitazone (PPAR-gamma agonist) resolves MASH and reduces fibrosis stage, but its use is limited by adverse effects including fluid retention, weight gain, and osteopenia.
Pioglitazone can resolve MASH and reduce liver scarring, but it causes weight gain and fluid retention, which can worsen heart failure risk. It is generally limited by these side effects, particularly in older women due to fracture risk.
GoodQualifiesHIGH confidence
It led to the resolution of MASH and reduction in the stage of fibrosis, but adverse effects limited its application. Fluid retention occurred, which increases the risk of heart failure, weight gain, and the appearance of osteopenia in older women, multiplying the possibility of pathological fractures
Why this rating
Described as having observed positive effects in histopathology-verified MASH.
Source
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković et al. · Diagnostics · 2024
DOI 10.3390/diagnostics14020229
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obeticholic acid (25 mg/day) improves liver fibrosis in patients with MASH and stage 2-3 fibrosis, but does not significantly resolve MASH activity compared to placebo.Good
- GLP-1 agonists (Semaglutide, Liraglutide) and dual GIP/GLP-1 agonists (Tirzepatide) are potential pharmacotherapies for MASLD/MASH due to their metabolic effects and ability to induce weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →